# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $8 price target.
On Thursday prior to the market open, Emergent BioSolutions announced it entered into a definitive agreement with Bora to sell ...
Benchmark analyst Robert Wasserman maintains Emergent BioSolutions (NYSE:EBS) with a Buy and raises the price target from $5...
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product...
Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171....